537 related articles for article (PubMed ID: 15719417)
1. Patient-perceived involvement and satisfaction in Parkinson's disease: effect on therapy decisions and quality of life.
Grosset KA; Grosset DG
Mov Disord; 2005 May; 20(5):616-9. PubMed ID: 15719417
[TBL] [Abstract][Full Text] [Related]
2. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.
Honig H; Antonini A; Martinez-Martin P; Forgacs I; Faye GC; Fox T; Fox K; Mancini F; Canesi M; Odin P; Chaudhuri KR
Mov Disord; 2009 Jul; 24(10):1468-74. PubMed ID: 19425079
[TBL] [Abstract][Full Text] [Related]
3. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease.
Weintraub D; Moberg PJ; Duda JE; Katz IR; Stern MB
J Am Geriatr Soc; 2004 May; 52(5):784-8. PubMed ID: 15086662
[TBL] [Abstract][Full Text] [Related]
4. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
Parkinson Study Group CALM Cohort Investigators
Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
[TBL] [Abstract][Full Text] [Related]
5. [Assessing quality of life in Parkinson's disease using the PDQ-39. A pilot study].
Martínez-Martín P; Frades Payo B; Fontán Tirado C; Martínez Sarriés FJ; Guerrero MT; del Ser Quijano T
Neurologia; 1997 Feb; 12(2):56-60. PubMed ID: 9147452
[TBL] [Abstract][Full Text] [Related]
6. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
Jost WH; Klasser M; Reichmann H
Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
[TBL] [Abstract][Full Text] [Related]
7. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease.
Nausieda PA; Pfeiffer RF; Tagliati M; Kastenholz KV; DeRoche C; Slevin JT
Clin Ther; 2005 Jan; 27(1):58-63. PubMed ID: 15763606
[TBL] [Abstract][Full Text] [Related]
8. Impact of non-motor symptoms on health-related and perceived quality of life in Parkinson's disease.
Santos-García D; de la Fuente-Fernández R
J Neurol Sci; 2013 Sep; 332(1-2):136-40. PubMed ID: 23890935
[TBL] [Abstract][Full Text] [Related]
9. Impact of the motor complications of Parkinson's disease on the quality of life.
Chapuis S; Ouchchane L; Metz O; Gerbaud L; Durif F
Mov Disord; 2005 Feb; 20(2):224-30. PubMed ID: 15384126
[TBL] [Abstract][Full Text] [Related]
10. The clinically important difference on the unified Parkinson's disease rating scale.
Shulman LM; Gruber-Baldini AL; Anderson KE; Fishman PS; Reich SG; Weiner WJ
Arch Neurol; 2010 Jan; 67(1):64-70. PubMed ID: 20065131
[TBL] [Abstract][Full Text] [Related]
11. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
12. Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's disease: impact on control of fluctuations and quality of life.
Puente V; De Fabregues O; Oliveras C; Ribera G; Pont-Sunyer C; Vivanco R; Cucurella G; Giralt E; Delgado T; Garcia C; Seoane A; Campo R
Parkinsonism Relat Disord; 2010 Mar; 16(3):218-21. PubMed ID: 19762271
[TBL] [Abstract][Full Text] [Related]
13. Parkinsonism in multiple system atrophy: natural history, severity (UPDRS-III), and disability assessment compared with Parkinson's disease.
Tison F; Yekhlef F; Chrysostome V; Balestre E; Quinn NP; Poewe W; Wenning GK
Mov Disord; 2002 Jul; 17(4):701-9. PubMed ID: 12210859
[TBL] [Abstract][Full Text] [Related]
14. Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations.
Marras C; Lang A; Krahn M; Tomlinson G; Naglie G;
Mov Disord; 2004 Jan; 19(1):22-8. PubMed ID: 14743356
[TBL] [Abstract][Full Text] [Related]
15. Apathy and depression in Parkinson disease.
Oguru M; Tachibana H; Toda K; Okuda B; Oka N
J Geriatr Psychiatry Neurol; 2010 Mar; 23(1):35-41. PubMed ID: 20015839
[TBL] [Abstract][Full Text] [Related]
16. Depressive symptoms impacting on health-related quality of life in early Parkinson's disease: results from Chinese L-dopa exposed cohort.
Qin Z; Zhang L; Sun F; Liu H; Fang X; Chan P;
Clin Neurol Neurosurg; 2009 Nov; 111(9):733-7. PubMed ID: 19665835
[TBL] [Abstract][Full Text] [Related]
17. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome.
Antonini A; Isaias IU; Canesi M; Zibetti M; Mancini F; Manfredi L; Dal Fante M; Lopiano L; Pezzoli G
Mov Disord; 2007 Jun; 22(8):1145-9. PubMed ID: 17661426
[TBL] [Abstract][Full Text] [Related]
18. [Neuropsychiatric problems in patients with Parkinson's disease].
Zhou MZ; Liu ZG; Gan J; Chen W; Lu LX; Wu JY
Zhonghua Yi Xue Za Zhi; 2008 Jun; 88(21):1442-5. PubMed ID: 18953846
[TBL] [Abstract][Full Text] [Related]
19. Quality of life in Polish patients with long-lasting Parkinson's disease.
Zach M; Friedman A; Sławek J; Derejko M
Mov Disord; 2004 Jun; 19(6):667-72. PubMed ID: 15197705
[TBL] [Abstract][Full Text] [Related]
20. Freezing of gait affects quality of life of peoples with Parkinson's disease beyond its relationships with mobility and gait.
Moore O; Peretz C; Giladi N
Mov Disord; 2007 Nov; 22(15):2192-5. PubMed ID: 17712856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
